| Literature DB >> 30021935 |
Fozia Shaheen1,2, Muhammad Hammad Aziz3,4, Mahvish Fatima5, Muhammad Ajmal Khan6,7, Faisal Ahmed8, Riaz Ahmad9, Muhammad Ashfaq Ahmad10, Turki S Alkhuraiji11, Muhammad Waseem Akram12, Rizwan Raza13, Syed Mansoor Ali14.
Abstract
Graphene-based materials have attracted considerable interest owing to their distinctive characteristics, such as their biocompatibility in terms of both their physical and intrinsic chemical properties. The use of nanomaterials with graphene as a biocompatible agent has increased due to an uptick in dedication from biomedical investigators. Here, GO-ZnO was characterized by X-ray diffraction (XRD), field emission scanning electron microscopy (FESEM), ultraviolet-visible (UV-Vis) spectroscopy, energy dispersive X-ray analysis (EDAX), and Raman spectroscopy for structural, morphological, and elemental analysis. The toxic extent of GO-ZnO was noted by a methyl-thiazole-tetrazolium (MTT), while cellular morphology was observed towards the MCF-7 cells using an inverted microscope at magnification 40×. The cytotoxic effect of GO-ZnO investigated the cell viability reduction in a dose-dependent manner, as well as prompted the cell demise/destruction in an apoptotic way. Moreover, statistical analysis was performed on the experimental outcomes, with p-values < 0.05 kept as significant to elucidate the results. The generation of reactive oxygen species (ROS) demonstrated the potential applicability of graphene in tumor treatment. These key results attest to the efficacy of GO-ZnO nanocomposites as a substantial candidate for breast malignancy treatment.Entities:
Keywords: cellular morphology; cytotoxicity; graphene oxide (GO); reactive oxygen species (ROS)
Year: 2018 PMID: 30021935 PMCID: PMC6070898 DOI: 10.3390/nano8070539
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1X-ray diffraction (XRD) structure of nanocomposites.
Figure 2(a) scanning electron microscopy (SEM) of graphene oxide (GO)-ZnO nanocomposites; (b) energy dispersive X-rays (EDAX) of GO-ZnO.
Figure 3Raman spectra of GO-ZnO nanocomposites.
Figure 4Ultraviolet visible absorption spectra of (a) GO; (b) ZnO; (c) GO-ZnO nanocomposites.
Figure 5Absorbance versus concentration of GO-ZnO nanocomposites.
Figure 6(a) cellular viability of GO-ZnO treated MCF-7 cells, t-test (* p < 0.05); (b) linear calibration plot of GO-ZnO vs. cell viability.
Figure 7Lactate Dehydrogenase (LDH) release (%) in MCF-7 cells following incubation with GO-ZnO nanocomposites after 24 h. Treated groups exhibited the statistically significant differences from the control group, as measured by the Student’s t-test (p < 0.05).
Figure 8GO-ZnO induced morphological variations in MCF-7 cells at magnification 40× (a) control; (b) 20 µg/mL; (c) 40 µg/mL; (d) 80 µg/mL; (e) 100 µg/mL.
Figure 9The outcomes of GO-ZnO represent the cell mortality of MCF-7 Cells. Treated groups displayed the statistically significant differences from the control group, as measured by the Student’s t-test (p < 0.05).
Figure 10(a) GO-ZnO liberated Reactive Oxygen Species (ROS) Fluorescence in breast cancerous cells; (b) a significant negative correlation between ROS and Cell viabiity.
Figure 11Fluorescent micrographs of (acridine orange/propidium iodide) AO/PI double stained MCF-7 cells that were treated with GO-ZnO nanocomposites (400× magnification). (a) untreated cells presenting normal cell structures; (b) treated MCF-7 cells after 12 h incubation; (c) MCF-7 cells after 24 h incubation. CmB: Membrane blabbing; CC: Chromatin condensation; VC: Viable cells, EA: Early apoptotic cells, LA: Late apoptotic cells, and AB: Apoptotic body.
Figure 12Quantum yield of singlet oxygen of GO-ZnO, ZnO and GO in contrast to MB.